RAS activation via CRLF2 signaling is a widespread mechanism in Down syndrome acute lymphoblastic leukemia regardless of RAS mutationsDavid Koschut(Nanyang Technological University), Dean Nižetić(Queen Mary University of London)bioRxiv (Cold Spring Harbor Laboratory)February 3, 202010.1101/2020.02.03.931725Cited by 0SaveCiteExport RISWatch citationsRelated PapersRAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia|Oncogene|2020|15Mechanical Stress Induces a Transient Suppression of Cytokine Secretion in Astrocytes Assessed at the Single‐Cell Level with a High‐Throughput Microfluidic Chip|Advanced Healthcare Materials|2021|13